Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs
ID
Morozova, Nataša
(
Author
),
ID
Zajc Avramovič, Mojca
(
Author
),
ID
Markelj, Gašper
(
Author
),
ID
Toplak, Nataša
(
Author
),
ID
Avčin, Tadej
(
Author
)
PDF - Presentation file,
Download
(966,01 KB)
MD5: 2D19D559F428C2EDCA38BD48C0857FDA
URL - Source URL, Visit
https://link.springer.com/article/10.1007/s10067-024-07012-4
Image galllery
Abstract
Objective: To determine the dynamics of serum levels of TNF-α in patients with juvenile idiopathic arthritis (JIA) treated with anti-TNF-α biological drugs and investigate their association with the disease activity. Methods: We conducted a single-centre, observational cohort study in 98 patients with JIA (30 boys, 68 girls, mean age 11.3 years) treated with anti-TNF-α biological drugs. Clinical examinations and laboratory assessments of serum levels of TNF-α were performed before starting therapy with biological drug and at 6-month intervals afterwards up to 2.5 years. Results: The analysis of serum levels of TNF-α in relation to the disease activity states showed the highest mean serum levels of TNF-α in patients on etanercept who had low disease activity states and in patients on adalimumab who had inactive disease. The correlation analysis in patients with JIA treated with etanercept or adalimumab showed a weak negative correlation between the serum levels of TNF-α and JADAS10 scores (p = 0.007), (r = – 0.177). Conclusion: The assessment of serum levels of TNF-α in children with JIA during treatment with etanercept or adalimumab is not a reliable biomarker of disease activity or immunological remission. Longitudinal measurement of TNF-α has no added clinical value in patients with JIA treated with anti-TNF-α biological drugs.
Language:
English
Keywords:
adalimumab
,
cytokines
,
etanercept
,
juvenile idiopathic arthritis
,
tumour necrosis factor-alpha
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2024
Number of pages:
Str. 2287-2293
Numbering:
Vol. 43, iss. 7
PID:
20.500.12556/RUL-160117
UDC:
61
ISSN on article:
0770-3198
DOI:
10.1007/s10067-024-07012-4
COBISS.SI-ID:
203660291
Publication date in RUL:
21.08.2024
Views:
53
Downloads:
3
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Clinical rheumatology
Shortened title:
Clin. rheumatol.
Publisher:
Springer Nature, International League of Associations for Rheumatology
ISSN:
0770-3198
COBISS.SI-ID:
6910681
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Projects
Funder:
ARRS - Slovenian Research Agency
Project number:
J3-3061
Name:
Klinične, imunološke in genetske značilnosti večorganskega vnetnega sindroma povezanega s COVID-19 pri otrocih in mladostnikih
Funder:
Other - Other funder or multiple funders
Funding programme:
University Medical Centre Ljubljana
Project number:
20190050
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back